Yvonne Huang, MD
Pulmonary Disease · Ann Arbor, MINPI 1184743338
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $91 of the $113 with a category attached, or 80.5%. Regeneron Healthcare Solutions, Inc. accounts for 62.1% of it on its own, with 2 other manufacturers making up the rest. That places this record below the midpoint for pulmonary disease clinicians in MI, where the typical reported total is $1,164.
Across 4 payments — averaging $28.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$70
- Mylan Specialty L.p.$22
- Novartis$21
Across 13 payments — averaging $82,462 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$557K
- Sanofi$515K
What the payments were for
- Food & beverage$9180%
- Education$2220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 2 | $70 |
| Mylan Specialty L.p. | 1 | $22 |
| Novartis | 1 | $21 |
How this compares
$113 in reported general payments places this provider in the 20th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 95 | $2,424,113 |
| CreonLipase/Protease/Amylase | 42 | $194,351 |
| CaystonAztreonam Lysine | 11 | $130,921 |
| ZenpepLipase/Protease/Amylase | 14 | $127,576 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,580 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $1,322 |
| Azithromycin | 14 | $525 |
| Omeprazole | 13 | $116 |
| Lorazepam | 13 | $20 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Ann Arbor
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Justin OldhamAnn Arbor$392K
- Kevin FlahertyAnn Arbor$328K
- Jose de CardenasAnn Arbor$115K
- Timothy BlackwellAnn Arbor$99K
- Philip ChoiAnn Arbor$54K
- Jeanette BrownAnn Arbor$38K
- Jeffrey CurtisAnn Arbor$37K
- Vibha LamaAnn Arbor$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.